Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 28, 2019 - Issue 5
Submit an article Journal homepage
79
Views
4
CrossRef citations to date
0
Altmetric
Editorial

An update on recent developments in the search for hepatitis C virus therapies with pan-genotypic efficacy

Guglielmo BorgiaDepartment of Clinical Medicine and Surgery - Section of Infectious Diseases, University of Naples Federico II, Naples, ItalyCorrespondence[email protected]
,
Riccardo ScottoDepartment of Clinical Medicine and Surgery - Section of Infectious Diseases, University of Naples Federico II, Naples, Italy
&
Antonio Riccardo BuonomoDepartment of Clinical Medicine and Surgery - Section of Infectious Diseases, University of Naples Federico II, Naples, Italy
Pages 395-397 | Published online: 10 Apr 2019

References

  • Gentile I, Scotto R, Zappulo E, et al. Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert Opin Investig Drugs. 2016;25(5):557–572. PubMed PMID: 26934419; eng.
  • Westerhoff M, Ahn J. Chronic hepatitis C and direct acting antivirals. Surg Pathol Clin. 2018 Jun;11(2):287–296. PubMed PMID: 29751875; eng.
  • Gentile I, Borgia F, Buonomo AR, et al. ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem. 2014;21(28):3261–3270.
  • Ansaldi F, Orsi A, Sticchi L, et al. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol. 2014 Aug 7;20(29):9633–9652. PubMed PMID: 25110404; PubMed Central PMCID: PMCPmc4123355. eng.
  • Buonomo AR, Scotto R, Pinchera B, et al. Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy. New Microbiol. 2018 Jan;41(1):26–29. PubMed PMID: 29112765; eng.
  • Lanini S, Easterbrook PJ, Zumla A, et al. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2016 Oct;22(10):833–838. PubMed PMID: 27521803; eng.
  • Hepatitis C Drug News for. 2018 No pipeline. [cited Dec 18]. Available from: https://www.hepatitiscentral.com/news/hepatitis-c-drug-news-for-2018-no-pipeline/
  • Good results for Sovaldi and Ravidasvir treating hepatitis C genotype 4. [cited Feb 2018]. Available from: https://www.hepmag.com/article/PYRAMID-Sovaldi-ravidasvir-28085-1528583872
  • Non-profit’s $300 hepatitis C cure as effective as $84,000 alternative. The Guardian. 2018 April 13th. [cited 2019 Feb]. Available from: https://www.theguardian.com/science/2018/apr/12/non-profits-300-hepatitis-c-cure-as-effective-as-84000-alternative
  • Lalezari J, Farrell G, Shah P, et al. PPI-668, a potent new pan-genotypic HCV NS5A inhibitor: phase 1 efficacy and safety. 63rd Annual Meeting of the American Association for the Study of Liver Diseases; 2012 Nov 9–12; Boston, MA. [cited Dec 18]. Available from: http://www.natap.org/2012/AASLD/AASLD_34.htm
  • Lalezari J, Glutzer E, Vig P, et al. Rapid and consistent virologic responses in a phase 2 trial of a new all-oral combination of faldaprevir, deleobuvir and PPI-668, with and without ribavirin, in patients with HCV genotype-1a infection. 2013, 64th Annual Meeting of the American Association for the Study of Liver Dis- eases; 2013 Nov 1–5; Washington DC: USA.
  • Esmat G, Elbaz T, El Raziky M, et al. Effectiveness of ravidasvir plus sofosbuvir in interferon-naive and treated patients with chronic hepatitis C genotype-4. J Hepatol. 2017 Sep 19. DOI:10.1016/j.jhep.2017.09.006 PubMed PMID: 28935432; eng.
  • Esmat G, El Raziky M, Gomaa A, et al. Final results of the pyramid 1 study, a phase 3 registrational trial of ravidasvir (PPI-668) and sofosbuvir in HCV genotype-4 patients: high rates of sustained viral clearance in cirrhotic and non-cirrhotic patients. J Hepatol. 2016;64(2):S770.
  • Gentile I, Maraolo AE, Buonomo AR, et al. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin Drug Discov. 2015 Dec;10(12):1363–1377. PubMed PMID: 26563720; eng.
  • Lim TS, Ahn SH. Use of sofosbuvir in chronic kidney disease: is it necessary? Clin Mol Hepatol. 2017 Dec;23(4):308–310. PubMed PMID: 28948751; PubMed Central PMCID: PMCPMC5760009. eng.
  • Gentile I, Borgia F, Zappulo E, et al. Efficacy and safety of sofosbuvir in treatment of chronic hepatitis C: the dawn of the a New Era. Rev Recent Clin Trials. 2013. doi:10.2174/1574887114666190306154650
  • Mendizabal M, Reddy KR. Chronic hepatitis C and chronic kidney disease: advances, limitations and unchartered territories. J Viral Hepat. 2017 Jun;24(6):442–453. PubMed PMID: 28107583; eng.
  • Borgia G, Maraolo AE, Buonomo AR, et al. The therapeutic potential of new investigational hepatitis C virus translation inhibitors. Expert Opin Investig Drugs. 2016 Oct;25(10):1209–1214. PubMed PMID: 27537604; eng.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.